PMGC Holdings Inc. announced that its wholly owned subsidiary, NorthStrive Biosciences Inc., has executed a definitive, exclusive license agreement with Modulant Biosciences LLC for the commercialization of EL-22 and EL-32, myostatin-engineered probiotics for muscle preservation in animal health. Under the agreement, Modulant will be responsible for development, manufacturing, regulatory, and commercialization activities for the licensed products in the animal health sector. The agreement includes provisions for sublicensing, shared ownership of improvements and new intellectual property, and ongoing regulatory compliance. The agreement excludes any human pharmaceutical or clinical applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652537-en) on February 11, 2026, and is solely responsible for the information contained therein.